Navigation Links
AMT Provides Business Update for the First Quarter 2010
Date:5/19/2010

AMSTERDAM, May 19, 2010 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (EuroNext Amsterdam: AMT), a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive. This report summarizes material events and AMT's financial position for the first quarter of 2010.

    Q1 2010 Highlights

    - EMA starts formal review of Glybera(R) dossier
    - Dossier validated by EMA on January 20, 2010
    - Day 120 questions from EMA expected second half of May 2010
    - Innovation Credit received from Dutch Government for Duchenne Muscular
      Dystrophy
    - Up to EUR 4 million funding, repayable only on successful
      commercialization
    - Supports 35% of development costs through to 2013
    - Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B
    - First patient dosed

Business Update

AMT's cash position* on March 31, 2010 amounted to EUR17.7 million compared to EUR22.6 million on December 31, 2009. The cash outflow in the first quarter of 2010, amounting to EUR4.9 million mainly represented operational cash flow. AMT employed 85 persons as of March 31, 2010. Total expenses in the first quarter of 2010 were EUR5.1 million compared to EUR4.9 million in the same period last year.

* The Company's cash position is composed of cash and cash equivalents.

Material events after March 31, 2010

On May 6, 2010'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CardioDynamics Provides 2007 Shareholder Meeting Update
2. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
3. NxStage Medical Provides Update on Medisystems Acquisition
4. VaxGen Files 2006 Financial Statements and Provides Cash Update
5. Signalife Provides Corporate Update
6. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
7. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
8. SGX Provides Update on BCR-ABL Collaboration
9. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
10. Pressure BioSciences, Inc. Provides Corporate Update
11. New Scrip Report Provides Strategic Insight on the Burgeoning Biosimilars Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Adult stem cells that are required ... not magical. However, many current regenerative medicine ... if they were magical. , Many current clinical ... “stem cell tourism,” are evaluating heterologous tissue stem ... regenerative medicine therapies. In reality, these are not ...
(Date:7/22/2014)... LAKES, N.J. , July 22, 2014 The ... BDX ) has declared a quarterly dividend of ... to holders of record on September 9, 2014. The indicated ... About BD BD is a leading medical technology ... of the world,s most pressing and evolving health needs. Our ...
(Date:7/22/2014)... metal nanoparticles in water with ultrasound and they,ll spin ... No one yet knows exactly. But researchers at the ... their speedand it,s fast. At up to 150,000 revolutions ... any nanoscale object submerged in liquid ever reported. , ... the possibility that they could be used not only ...
(Date:7/22/2014)... Nuclear reactors are used to produce electricity ... chain reaction in nuclear reactors is used to create ... a power- generating turbine. Currently nuclear reactors are used ... production. Nuclear reactor market is expected to grow in ... nuclear reactor projects. , Early buyers will receive 10% ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 3
... Arpida Ltd,(SIX: ARPN) announced today its financial results for the year ending 31,December ... - Setback in regulatory process for intravenous iclaprim in US, ... - Top-line results of "intravenous-to-oral" Phase II trial with oral, ... change, - Share placing, Cash ...
... Feb. 25 Cerimon Pharmaceuticals, Inc., announced ... its once-daily topical diclofenac sodium patch Phase III program. ... Phase III clinical studies with Cerimon,s diclofenac patch. ... Cerimon,s diclofenac patch compared to placebo for the treatment ...
... SAN DIEGO and MONTREAL, Feb. 25 Speid ... consultancy firm today announced that it has entered ... success rates of new drug compounds using Genizon,s ... climate in which innovative pharmaceutical and biotechnology companies ...
Cached Biology Technology:Arpida Announces Full Year 2008 Financial Results 2Arpida Announces Full Year 2008 Financial Results 3Arpida Announces Full Year 2008 Financial Results 4Arpida Announces Full Year 2008 Financial Results 5Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain 2Speid & Associates Partners With Genizon BioSciences to Reduce Attrition Rates of New Drug Compounds 2
(Date:7/22/2014)... research team from the National Institute of Standards ... has demonstrated a dramatically improved technique for analyzing ... vibration "signatures." The new NIST technique is an ... spectroscopy, but one that delivers signals that are ... scattering, and 100 times stronger than obtained from ...
(Date:7/22/2014)... of nanomaterials for application in devices may be addressed ... conducted by scientists from the National University of Singapore ... and low cost technique involving a focused laser beam, ... Haur from the Department of Physics at the NUS ... different types of materials can be controlled and modified, ...
(Date:7/22/2014)... milk helps make their bones strong or that fish is food ... if something is good for us, it must surely taste bad? ... Research , when children hear about the benefits of healthy food, ... food is presented to children as making them strong or as ... read or count, they would conclude the food is not as ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3NUS scientists use low cost technique to improve properties and functions of nanomaterials 2NUS scientists use low cost technique to improve properties and functions of nanomaterials 3
... 2010): Today, the Association for Molecular Pathology (AMP) submitted written ... the National Institutes of Health (NIH) for its Genetic Test ... to formulate a comprehensive response to the RFI. "With ... setting, AMP is able to inform the NIH on the ...
... While pundits write obituaries for the 2010 climate bill, ... the world. We are losing species and ecosystems are unraveling ... We need new tools and strategies to deal with these ... to announce the launch of their new Climate Adaptation Knowledge ...
... PHILADELPHIAIn 1824, three years before he began to publish his ... Audubon (1785-1851), the eminent artist of American birds and animals, ... the design for a New Jersey bank note. Although the ... in two separate diary entries, no one has ever been ...
Cached Biology News:AMP responds to Genetic Test Registry request for information 2CAKE offers way forward for climate change adaptation 2Discovered: Audubon's first engraving of a bird 2
...
... Forma Incubated Orbital Shakers combine high ... performance and ease of use. The ... allowing the unit to run at ... The unit's class-leading temperature range is ...
The 891 45° Fixed Angle Rotor is designed to provide aerosol containment and can be removed from a centrifuge (seal entact) and opened under an environmental hood....
... have the durability to run ... and the uniformity and contamination ... applications. Heavily built with ... stackers are designed for ease ...
Biology Products: